A Scientific Advancement In The Treatment Of HR+, HER2- Metastatic Breast Cancer

IBRANCE® (palbociclib) is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast cancer.

IBRANCE Is Taken With A Hormonal Therapy

IBRANCE is taken with a hormonal therapy and is used to treat hormone receptor positive (HR+), HER2- metastatic breast cancer. In combination with any aromatase inhibitor,* IBRANCE is for postmenopausal women as their first hormonal based therapy. In combination with fulvestrant, IBRANCE is for women who have previously received hormonal therapy for their disease. Talk to your healthcare team to learn if IBRANCE is right for you.

Which Type Of Breast Cancer Is IBRANCE For?

IBRANCE is for women with hormone receptor positive (HR+), HER2- metastatic breast cancer — or HR+/HER2-.

If your subtype is HER2-, your cancer cells have less HER2 protein expression and, therefore, are less likely to respond to anti-HER2 therapies.

Hormone receptor positive includes both ER+ (estrogen receptor positive) and/or PR+ (progesterone receptor positive) subtypes.

Hormone receptor positive (HR+), HER2- is the most common subtype of metastatic breast cancer, representing roughly 60% of all cases. If your subtype is ER+ and/or PR+, you’re more likely to respond to hormone therapies, like an aromatase inhibitor or fulvestrant, that reduce the effects of hormones.

*Aromatase inhibitor is a class of therapy that includes: letrozole, anastrozole, and exemestane.


About IBRANCE® (palbociclib) Capsules for MBC | Safety Info
See risks and benefits of IBRANCE. Learn about IBRANCE® (palbociclib) capsules combination regimen for certain women with HR+/HER2- metastatic breast cancer.

Slowing The Progression Of Metastatic Breast Cancer


IBRANCE (palbociclib) is in a class of drugs called CDK 4/6 inhibitors that work to put the brakes on cell growth and division in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see the Important Safety Information to learn more.

Learn How IBRANCE & Hormonal Therapies Work Together

IBRANCE and hormonal therapies bring the power of two therapies together to help delay the progression of a certain type of metastatic breast cancer.

Use the green arrows to navigate the animation below, demonstrating how IBRANCE works to inhibit CDK 4/6 and how hormonal therapies play a role in reducing the effects of hormones in the body.


How IBRANCE® (palbociclib) Capsules Work | Safety Info
See risks & benefits of IBRANCE. Learn how IBRANCE® (palbociclib) capsules can slow the progression of metastatic breast cancer.